[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"art-adherence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:art-adherence":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100602570","reactive-driven-support-for-treatment-adherence-resilience-and-thriving-restart-clinical-trial-100602570",false,"NCT07125235","Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial","Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) mHealth Randomized Controlled Hybrid Type I Effectiveness Implementation Trial","reSTART","Inclusion Criteria:\n\n* Prescribed antiretroviral therapy (ART) with a tenofovir-based regimen.\n* Documented virologic non-suppression, urine tenofovir testing without tenofovir detected, or self-reported adherence \\\u003C100%.\n* Reports stimulant use.\n* Has a mailing address within the U.S.\n* Currently has a smartphone with photo capabilities.\n\nExclusion Criteria:\n\n* Have any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions.\n* Not prescribed ART.\n* Unwilling to perform urine self-testing or to attend a local Quest site for viral load monitoring.\n* Unable to provide a hair sample of \\~50-100 strands of hair that are non-gray, not bleached, and at least 1cm in length","MALE","18 Years","70 Years",{"count":21,"type":22},270,"ESTIMATED","INTERVENTIONAL",[25],"NA","Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants.",[28,29,30],"Behavioral Intervention","Viral Suppression of HIV Infection","ART Adherence",[32,33,34],"HIV","Stimulant Use","mHealth","RECRUITING","2026-03-11",{"date":38,"type":39},"2026-03-13","ACTUAL",{"date":41,"type":39},"2026-02-09",{"date":43,"type":22},"2028-07-30",{"name":45,"class":46},"University of California, San Francisco","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100544918","efficacy-of-mhealth--e-navigator-stepped-care-intervention-for-art-adherence-among-latino-men-with-hiv-100544918","NCT06375135","Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV","Project STEP","1. Latino or Hispanic\n2. Self-report male sex\n3. Age 18 or older\n4. Diagnosed with HIV and prescribed ART least 1 month prior to study screening and enrollment\n5. Suboptimal adherence defined as (1) laboratory evidence of at least one detectable viral load in the past 12 months (≥20 copies\u002FmL), (2) electronic medical record of at least one \\\u003C90% 30-day adherence period in the past 12 months, or (3) self-reported \\\u003C90% past 30-day adherence.\n6. Cell phone ownership and SMS use: Participants must own a personal cell phone for the intervention.",{"count":56,"type":22},250,[25],"The goal of this study is to evaluate the efficacy of stepped care strategies to improve ART adherence among adult Latino men with HIV using a sequential, multiple assignment, randomized trial (SMART). The trial will compare a stepped care strategy of delivering TXTXT (\"Treatment Text\") first and stepping up to remote patient navigation for non-responders vs. a stepped care strategy of delivering TXTXT + e-Navigation first and stepping up to EMA-supported e-Navigation for non-responders. Both TXTXT and the foundations of the e-Navigation interventions are CDC evidence-based interventions (EBI). We propose to use a SMART design which explicitly allows building, testing, and optimizing stepped care strategies without compromising rigor or randomization. We propose three specific aims:\n\nAim 1. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two static (non-stepped) treatment regimens (TXTXT alone vs. TXTXT + e-Navigation) on ART adherence and viral suppression among Latino men with HIV. Hypothesis 1a. TXTXT + e-Navigation will be more efficacious than TXTXT alone. Aim 2. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two stepped care strategies (TXTXT with added e-Navigation for non-responders vs. TXTXT + e-Navigation with added EMA support for non-responders) on ART adherence and viral suppression among Latino men with HIV. Hypothesis 2a: TXTXT + e-Navigation with added EMA support for non-responders at the 3-month follow-up will be more efficacious than TXTXT with added e-Navigation for non-responders at the 3-month follow-up. Aim 3. Identify baseline and time-varying moderators on the association between stepped care strategy and ART adherence and viral suppression among Latino men with HIV. Hypotheses 3a-c: TXTXT with added e-Navigation for non-responders will be less efficacious than TXTXT + e-Navigation with added EMA support for non-responders for individuals who are: (a) older at baseline, or report (b) substance use, or (c) symptoms of depression between baseline and the 3-month follow-up.",[30],[61,62,63,64,65,66,67,68,69,70],"HIV\u002FAIDS","Treatment text","Ecological Momentary Assessment","Antiretroviral therapy adherence","medication adherence","viral suppression","HIV care strategies","Latino","Hispanic","SMART design","2026-01-28",{"date":73,"type":39},"2026-01-30",{"date":75,"type":39},"2024-06-06",{"date":77,"type":22},"2027-03-31",{"name":79,"class":46},"Florida International University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":47},"100548639","randomized-trial-to-optimize-virologic-suppression-rates-using-a-point-of-care-urine-monitoring-assay-roving-puma-100548639","NCT06423612","Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING PUMA)","ROVING-PUMA","Inclusion Criteria:\n\nAim 1: Individuals ≥18 years of age at the initial screening visit living with HIV, prescribed ART for at least three months, and are not virally suppressed.\n\nAim 2: Same as Aim 1 for the acceptability survey and in-depth interviews. HIV care providers in the selected clinic sites for the feasibility survey and in-depth interviews.\n\nAim 3: Same as Aim 1 for the cost-effectiveness study.\n\nExclusion Criteria:\n\n* Currently enrolled in another ART adherence intervention\n* Patients on ART regimen that does not include Tenofovir\n* HIV care providers from non-study sites Failure to provide written consent",true,"ALL",{"count":90,"type":22},500,[25],"Antiretroviral therapy (ART) has significantly decreased the morbidity and mortality of HIV infection. However, adherence challenges in taking daily oral ART persist. A retrospective cohort study across 31 countries from 2010-19 reported that only 65% of people with HIV (PWH) on ART exhibited virologic suppression (VS) three years after starting ART;1 the rate of VS in South Africa among PWH on ART is 60-65%. Adherence barriers span individual and structural factors, such as stigma, recall difficulties, housing and\u002For food insecurity, mental illness, substance use, transportation, stock-outs, and other factors that vary by country and population.\n\nAdherence interventions can benefit from direct objective adherence monitoring. Pharmacologic metrics of adherence assess drug levels in plasma, dried blood spots, hair (a metric our group pioneered) or urine and predict outcomes more accurately than self-reported adherence. However, most of these metrics preclude real-time assessment, requiring expensive laboratory equipment and trained laboratory personnel. Thus, few adherence interventions have successfully incorporated objective metrics, likely due to laboratory and shipping delays. A low-cost (\\\u003C$2\u002Ftest) point-of-care adherence metric - developed by our group - should allow for real-time biofeedback and improve the impact of metric-driven adherence interventions.",[30],[95,96,97,98,99,100,101],"ART","Adherence","South Africa","Viral Suppression","ART resistance","POC urine assay","TDF assay","2025-07-02",{"date":104,"type":39},"2025-07-04",{"date":106,"type":39},"2025-05-08",{"date":108,"type":22},"2026-11-30",{"name":45,"class":46}]